Skip to main content

News

You are here

UM Ventures News

UMD, UMB Strategic Partnership Announces Expansion of Interdisciplinary Research at Cole Field House

The University of Maryland, College Park and the University of Maryland, Baltimore are expanding the research and clinical scope at Cole Field House.

University of Maryland Ranks Among Top 100 Worldwide for Patents

The NAI and IPO have ranked the University of Maryland No. 27 in the world and No. 11 among U.S. public institutions for patents awarded in 2016.

Cellth Systems and University of Maryland Enter License Agreement to Advance New Circulating-Tumor-Cell-Analysis Technology

Cellth Systems has been granted exclusive rights for the commercial development of cell-tethering that allows analysis of circulating tumor cells (CTCs).

IBBR Awarded $6 Million NIH Grant for Structure-Based Design of a Hepatitis C Vaccine

The Institute for Bioscience and Biotechnology Research (IBBR) has been awarded a $6.0 million grant to develop a vaccine to prevent hepatitis C virus.

This startup is developing a vaccine for staph infections

Serenta Biotechnology, which is based in Gaithersburg, is working to build on technology that was effective in animal trials.

BBJ: Startup's Tech Matches Cancer Patients with Chemo, Drugs

A local startup wants to help doctors determine which drugs and chemotherapies will best treat different types of cancer.

University of Maryland, Baltimore and Serenta Team Up to Fight Staph Infections

The University of Maryland, Baltimore (UMB) has granted worldwide, exclusive licensing rights for a new vaccine technology to Serenta Biotechnology, LLC.

Governor Larry Hogan Announces Excel Maryland Initiative to Grow Life Sciences and Cyber Startups

Today opened Maryland’s inaugural Governor’s Business Summit before a crowd of more than 700 business, education, and community leaders.

Biogen Acquires Remedy Pharmaceuticals’ CIRARA™ for Large Hemispheric Stroke

Biogen (NASDAQ: BIIB) announced today that it has completed an asset purchase of Remedy Pharmaceuticals’ Phase 3 candidate, CIRARA™ (intravenous glyburide).

Pages